{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:56:42Z","timestamp":1790150202688,"version":"4.0.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1038\/s41584-020-0451-z","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T15:03:54Z","timestamp":1592579034000},"page":"465-470","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":152,"title":["COVID-19 revisiting inflammatory pathways of arthritis"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8740-9615","authenticated-orcid":false,"given":"Georg","family":"Schett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Manger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8310-7820","authenticated-orcid":false,"given":"David","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Caporali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,19]]},"reference":[{"key":"451_CR1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265\u2013269 (2020).","journal-title":"Nature"},{"key":"451_CR2","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","volume":"323","author":"Z Wu","year":"2020","unstructured":"Wu, Z. & McGoogan, J. M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) in China. JAMA 323, 1239\u20131242 (2020).","journal-title":"JAMA"},{"key":"451_CR3","doi-asserted-by":"publisher","DOI":"10.7326\/M20-2003","author":"D Wichmann","year":"2020","unstructured":"Wichmann, D. et al. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann. Intern. Med. https:\/\/doi.org\/10.7326\/M20-2003 (2020).","journal-title":"Ann. Intern. Med."},{"key":"451_CR4","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/S0140-6736(03)13364-8","volume":"361","author":"KL Hon","year":"2003","unstructured":"Hon, K. L. et al. Clinical presentations and outcome of severe acute respiratory syndrome in children. Lancet 361, 1701\u20131703 (2003).","journal-title":"Lancet"},{"key":"451_CR5","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(20)31129-6","volume":"395","author":"RM Viner","year":"2020","unstructured":"Viner, R. M. & Whittaker, E. Kawasaki-like disease: emerging complication during the COVID-19 pandemic. Lancet 395, 1741\u20131743 (2020).","journal-title":"Lancet"},{"key":"451_CR6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.7861\/clinmedicine.16-2-129","volume":"16","author":"M Marks","year":"2016","unstructured":"Marks, M. & Marks, J. L. Viral arthritis. Clin. Med. 16, 129\u2013134 (2016).","journal-title":"Clin. Med."},{"key":"451_CR7","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/v10100515","volume":"10","author":"N Friedman","year":"2018","unstructured":"Friedman, N. et al. Human coronavirus infections in Israel: epidemiology, clinical symptoms and summer seasonality of HCoV-HKU1. Viruses 10, 515 (2018).","journal-title":"Viruses"},{"key":"451_CR8","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"W-J Guan","year":"2020","unstructured":"Guan, W.-J. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708\u20131720 (2020).","journal-title":"N. Engl. J. Med."},{"key":"451_CR9","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1086\/420743","volume":"38","author":"MD Christian","year":"2004","unstructured":"Christian, M. D., Poutanen, S. M., Loutfy, M. R., Muller, M. P. & Low, D. E. Severe acute respiratory syndrome. Clin. Infect. Dis. 38, 1420\u20131427 (2004).","journal-title":"Clin. Infect. Dis."},{"key":"451_CR10","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1142\/S0192415X06004417","volume":"34","author":"S Li","year":"2006","unstructured":"Li, S. et al. Symptom combinations associated with outcome and therapeutic effects in a cohort of cases with SARS. Am. J. Chin. Med. 34, 937\u2013947 (2006).","journal-title":"Am. J. Chin. Med."},{"key":"451_CR11","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0140-6736(19)33221-0","volume":"395","author":"ZA Memish","year":"2020","unstructured":"Memish, Z. A., Perlman, S., Van Kerkhove, M. D. & Zumla, A. Middle East respiratory syndrome. Lancet 395, 1063\u20131077 (2020).","journal-title":"Lancet"},{"key":"451_CR12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","volume":"395","author":"CD Russel","year":"2020","unstructured":"Russel, C. D. et al. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 395, 473\u2013475 (2020).","journal-title":"Lancet"},{"key":"451_CR13","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(03)13412-5","volume":"361","author":"JSM Peiris","year":"2003","unstructured":"Peiris, J. S. M. et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361, 1767\u20131772 (2003).","journal-title":"Lancet"},{"key":"451_CR14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030343","volume":"3","author":"LJ Stockman","year":"2006","unstructured":"Stockman, L. J., Bellamy, R. & Garner, P. SARS: systematic review of treatment effects. PLoS Med. 3, e343 (2006).","journal-title":"PLoS Med."},{"key":"451_CR15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13075-019-1977-9","volume":"21","author":"YB Joo","year":"2019","unstructured":"Joo, Y. B., Lim, Y.-H., Kim, K.-J., Park, K.-S. & Park, Y.-J. Respiratory viral infections and the risk of rheumatoid arthritis. Arthritis Res. Ther. 21, 199 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"451_CR16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280.e8 (2020).","journal-title":"Cell"},{"key":"451_CR17","doi-asserted-by":"crossref","first-page":"4411","DOI":"10.1210\/en.2015-1556","volume":"156","author":"KB Pedersen","year":"2015","unstructured":"Pedersen, K. B. et al. Dynamics of ADAM17-mediated shedding of ACE2 applied to pancreatic islets of male db\/db mice. Endocrinology 156, 4411\u20134425 (2015).","journal-title":"Endocrinology"},{"key":"451_CR18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/jmv.25709","volume":"92","author":"J Liu","year":"2020","unstructured":"Liu, J. et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J. Med. Virol. 92, 491\u2013494 (2020).","journal-title":"J. Med. Virol."},{"key":"451_CR19","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.stemcr.2019.02.013","volume":"12","author":"H Katsura","year":"2019","unstructured":"Katsura, H. et al. IL-1 and TNF\u03b1 contribute to the inflammatory niche to enhance alveolar regeneration. Stem Cell Rep. 12, 657\u2013666 (2019).","journal-title":"Stem Cell Rep."},{"key":"451_CR20","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/gerona\/glu197","volume":"70","author":"M Starr","year":"2015","unstructured":"Starr, M. et al. Age-associated increase in cytokine production during systemic inflammation \u2014 II: the role of IL-1\u03b2 in age-dependent IL-6 upregulation in adipose tissue. J. Gerontol. 70, 1508\u20131515 (2015).","journal-title":"J. Gerontol."},{"key":"451_CR21","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-08831-9","volume":"10","author":"I Angelidis","year":"2019","unstructured":"Angelidis, I. et al. An atlas of the aging lung mapped by single cell transcriptomics and deep tissue proteomics. Nat. Commun. 10, 963 (2019).","journal-title":"Nat. Commun."},{"key":"451_CR22","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497\u2013506 (2020).","journal-title":"Lancet"},{"key":"451_CR23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41577-020-0312-7","volume":"20","author":"G Schett","year":"2020","unstructured":"Schett, G., Sticherling, M. & Neurath, M. F. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nat. Rev. Immunol. 20, 271\u2013272 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"451_CR24","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1128\/JVI.01792-08","volume":"83","author":"T Yoshikawa","year":"2009","unstructured":"Yoshikawa, T. et al. Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. J. Virol. 83, 3039\u20133048 (2009).","journal-title":"J. Virol."},{"key":"451_CR25","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.virol.2007.04.009","volume":"365","author":"X Zhang","year":"2007","unstructured":"Zhang, X. et al. Nucleocapsid protein of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-\u03baB. Virology 365, 324\u2013335 (2007).","journal-title":"Virology"},{"key":"451_CR26","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2004-10-4166","volume":"106","author":"HK Law","year":"2005","unstructured":"Law, H. K. et al. Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood 106, 2366\u20132374 (2005).","journal-title":"Blood"},{"key":"451_CR27","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00165-13","volume":"4","author":"L Josset","year":"2013","unstructured":"Josset, L. et al. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. mBio 4, e00165-13 (2013).","journal-title":"mBio"},{"key":"451_CR28","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.4049\/jimmunol.1100917","volume":"187","author":"G Ryzhakov","year":"2011","unstructured":"Ryzhakov, G. et al. IL-17 boosts proinflammatory outcome of antiviral response in human cells. J. Immunol. 187, 5357\u20135362 (2011).","journal-title":"J. Immunol."},{"key":"451_CR29","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.4373","volume":"23","author":"S Rauber","year":"2017","unstructured":"Rauber, S. et al. Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells. Nat. Med. 23, 938\u2013944 (2017).","journal-title":"Nat. Med."},{"key":"451_CR30","volume":"7","author":"Z Chen","year":"2016","unstructured":"Chen, Z. et al. TH2 and eosinophil responses suppress inflammatory arthritis. Nat. Commun. 7, 11596 (2016).","journal-title":"Nat. Commun."},{"key":"451_CR31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.55563\/clinexprheumatol\/xcdary","volume":"38","author":"P Sarzi-Puttini","year":"2020","unstructured":"Sarzi-Puttini, P. et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin. Exp. Rheumatol. 38, 337\u2013342 (2020).","journal-title":"Clin. Exp. Rheumatol."},{"key":"451_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/art.41285","author":"LA Henderson","year":"2020","unstructured":"Henderson, L. A. et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.41285 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"451_CR33","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","volume":"20","author":"J Stebbing","year":"2020","unstructured":"Stebbing, J. et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect. Dis. 20, 400\u2013402 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"451_CR34","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00281-017-0629-x","volume":"39","author":"R Channappanavar","year":"2017","unstructured":"Channappanavar, R. & Perlman, S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 39, 529\u2013539 (2017).","journal-title":"Semin. Immunopathol."},{"key":"451_CR35","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1172\/JCI137647","volume":"130","author":"SF Pedersen","year":"2020","unstructured":"Pedersen, S. F. & Ho, Y. C. SARS-CoV-2: a storm is raging. J. Clin. Invest. 130, 2202\u20132205 (2020).","journal-title":"J. Clin. Invest."},{"key":"451_CR36","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","volume":"117","author":"X Xu","year":"2020","unstructured":"Xu, X. et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl Acad. Sci. USA 117, 10970\u201310975 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"451_CR37","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04380961 (2020)."},{"key":"451_CR38","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04324021 (2020)."},{"key":"451_CR39","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04348448 (2020)."},{"key":"451_CR40","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1165\/rcmb.2012-0339OC","volume":"48","author":"Y Qian","year":"2013","unstructured":"Qian, Y. et al. Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome\u2013coronavirus. Am. J. Respir. Cell Mol. Biol. 48, 742\u2013748 (2013).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"451_CR41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1185\/030079903125002757","volume":"20","author":"E Tobinick","year":"2004","unstructured":"Tobinick, E. TNF-\u03b1 inhibition for potential therapeutic modulation of SARS coronavirus infection. Curr. Med. Res. Opin. 20, 39\u201340 (2004).","journal-title":"Curr. Med. Res. Opin."},{"key":"451_CR42","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(20)30858-8","volume":"395","author":"M Feldmann","year":"2020","unstructured":"Feldmann, M. et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet 395, 1407\u20131409 (2020).","journal-title":"Lancet"},{"key":"451_CR43","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1002\/1521-4141(200109)31:9<2566::AID-IMMU2566>3.0.CO;2-L","volume":"31","author":"T Hussell","year":"2001","unstructured":"Hussell, T., Pennycook, A. & Openshaw, P. J. Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur. J. Immunol. 31, 2566\u20132573 (2001).","journal-title":"Eur. J. Immunol."},{"key":"451_CR44","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/annrheumdis-2020-217424","volume":"79","author":"S Monti","year":"2020","unstructured":"Monti, S. et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann. Rheum. Dis. 79, 667\u2013668 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"451_CR45","unstructured":"Chinese Clinical Trial Registry. ChiCTR.org http:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49889 (2020)."},{"key":"451_CR46","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565\u2013574 (2020).","journal-title":"Lancet"},{"key":"451_CR47","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","volume":"395","author":"P Richardson","year":"2020","unstructured":"Richardson, P. et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 395, e30\u2013e31 (2020).","journal-title":"Lancet"},{"key":"451_CR48","unstructured":"US Department of Health and Human Services. Coronavirus (COVID-19). NIH.gov https:\/\/www.nih.gov\/health-information\/coronavirus (2020)."},{"key":"451_CR49","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/ni.2027","volume":"12","author":"L Codarri","year":"2011","unstructured":"Codarri, L. et al. ROR\u03b3t drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 12, 560\u2013567 (2011).","journal-title":"Nat. Immunol."},{"key":"451_CR50","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04341116 (2020)."},{"key":"451_CR51","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2474-13-158","volume":"13","author":"WA Blumentals","year":"2012","unstructured":"Blumentals, W. A. et al. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet. Disord. 13, 158 (2012).","journal-title":"BMC Musculoskelet. Disord."},{"key":"451_CR52","doi-asserted-by":"crossref","unstructured":"An, P. et al. Protection of 318 inflammatory bowel disease patients from the outbreak and rapid spread of COVID-19 infection in Wuhan, China. https:\/\/ssrn.com\/abstract=3543590 (Social Science Research Network, 2020).","DOI":"10.2139\/ssrn.3543590"},{"key":"451_CR53","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.03.062","author":"L Norsa","year":"2020","unstructured":"Norsa, L. et al. Uneventful course in IBD patients during SARS-CoV-2 outbreak in northern Italy. Gastroenterology https:\/\/doi.org\/10.1053\/j.gastro.2020.03.062 (2020).","journal-title":"Gastroenterology"},{"key":"451_CR54","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3389\/fmicb.2019.01057","volume":"10","author":"L Velazquez-Salinas","year":"2019","unstructured":"Velazquez-Salinas, L. et al. The role of interleukin-6 during viral infection. Front. Microbiol. 10, 1057 (2019).","journal-title":"Front. Microbiol."},{"key":"451_CR55","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/vaccines4030023","volume":"4","author":"S Fleming","year":"2016","unstructured":"Fleming, S. Viral inhibition of the IFN-induced JAK\/STAT signalling pathway: development of live attenuated vaccines by mutation of viral-encoded IFN-antagonists. Vaccines 4, 23 (2016).","journal-title":"Vaccines"},{"key":"451_CR56","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","volume":"58","author":"K Bechman","year":"2019","unstructured":"Bechman, K. et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology 58, 1755\u20131766 (2019).","journal-title":"Rheumatology"},{"key":"451_CR57","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-14-321","volume":"14","author":"T Kelesidis","year":"2014","unstructured":"Kelesidis, T., Mastoris, I., Metsini, A. & Tsiodras, S. How to approach and treat viral infections in ICU patients. BMC Infect. Dis. 14, 321 (2014).","journal-title":"BMC Infect. Dis."},{"key":"451_CR58","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41392-020-0148-4","volume":"5","author":"L Tan","year":"2020","unstructured":"Tan, L. et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal. Transduct. Targ. Ther. 5, 33 (2020).","journal-title":"Signal. Transduct. Targ. Ther."},{"key":"451_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30262-0","author":"EG Favalli","year":"2020","unstructured":"Favalli, E. G., Biggioggero, M., Maioli, G. & Caporali, R. Baricitinib for COVID-19: a suitable treatment? Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/S1473-3099(20)30262-0 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"451_CR60","doi-asserted-by":"crossref","first-page":"105967","DOI":"10.1016\/j.ijantimicag.2020.105967","volume":"55","author":"D Praveen","year":"2020","unstructured":"Praveen, D., Chowdary, P. R. & Aanandhi, M. V. Baricitinib, a Janus kinase inhibitor, not an ideal option for management of COVID 19. Int. J. Antimicrob. Agents 55, 105967 (2020).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"451_CR61","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","volume":"19","author":"LeT Thanh","year":"2020","unstructured":"Thanh, Le. T. et al. The COVID-19 vaccine development landscape. Nat. Rev. Drug Discov. 19, 305\u2013306 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"451_CR62","first-page":"317","volume":"36","author":"PL Meroni","year":"2018","unstructured":"Meroni, P. L., Zavaglia, D. & Girmenia, C. Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs. Clin. Exp. Rheumatol. 36, 317\u2013328 (2018).","journal-title":"Clin. Exp. Rheumatol."},{"key":"451_CR63","doi-asserted-by":"crossref","first-page":"102539","DOI":"10.1016\/j.autrev.2020.102539","volume":"19","author":"D Marotto","year":"2020","unstructured":"Marotto, D. & Sarzi-Puttini, P. What is the role of rheumatologists in the era of COVID-19? Autoimmun. Rev. 19, 102539 (2020).","journal-title":"Autoimmun. Rev."},{"key":"451_CR64","doi-asserted-by":"publisher","DOI":"10.1056\/CAT.20.0093","author":"JE Hollander","year":"2020","unstructured":"Hollander, J. E. & Sites, F. D. The transition from reimagining to recreating health care is now. NEJM Catalyst https:\/\/doi.org\/10.1056\/CAT.20.0093 (2020).","journal-title":"NEJM Catalyst"},{"key":"451_CR65","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1136\/annrheumdis-2020-217367","volume":"79","author":"FR Spinelli","year":"2020","unstructured":"Spinelli, F. R., Ceccarelli, F., Di Franco, M. & Conti, F. To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic. Ann. Rheum. Dis. 79, 666\u2013667 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"451_CR66","unstructured":"European Medicines Agency. COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes. EMA.europa.EU https:\/\/www.ema.europa.eu\/en\/news\/covid-19-chloroquine-hydroxychloroquine-only-be-used-clinical-trials-emergency-use-programmes (2020)."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41584-020-0451-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-020-0451-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-020-0451-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:22:17Z","timestamp":1684621337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-020-0451-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,19]]},"references-count":66,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["451"],"URL":"https:\/\/doi.org\/10.1038\/s41584-020-0451-z","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,19]]},"assertion":[{"value":"29 May 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}